Related Experiment Video
Updated: May 16, 2026

04:33
CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics
Published on: December 8, 2023
A peptide nanofibrous indicator for eye-detectable cancer cell identification
Chang-Sheng Chen1, Xiao-Ding Xu, Ya Wang
1Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, PR China.
Small (Weinheim an Der Bergstrasse, Germany)
|December 11, 2012
Summary
A novel peptide nanofibrous indicator (NFI) detects hepatocellular carcinoma (HCC) cells. This indicator changes color, enabling unaided eye identification of cancer cells for improved diagnostics.
Area of Science:
- Biomaterials Science
- Chemical Biology
- Cancer Diagnostics
Background:
- Sialyl Lewis X tetrasaccharide is overexpressed in hepatocellular carcinoma.
- Early detection of liver cancer is crucial for patient outcomes.
- Current diagnostic methods can be invasive or require specialized equipment.
Purpose of the Study:
- To develop a novel peptide nanofibrous indicator (NFI) for specific detection of hepatocellular carcinoma (HCC) cells.
- To create a visual detection method for cancer cells that is easily observable.
- To establish a new platform for cancer cell identification.
Main Methods:
- Fabrication of a peptide nanofibrous indicator (NFI) by mixing a borono-peptide with alizarin red S.
- Utilizing binding and self-assembly processes for indicator formation.
- Assessing the NFI's response to sialyl Lewis X tetrasaccharide and HepG2 cells.
Main Results:
- The NFI showed an intense response to sialyl Lewis X tetrasaccharide.
- The NFI specifically recognized human hepatocellular liver carcinoma (HepG2) cells.
- A strong binding-induced displacement resulted in an eye-detectable color change.
Conclusions:
- The developed NFI enables specific and visual detection of HCC cells.
- This technique offers a simple, unaided eye method for cancer cell identification.
- The NFI presents an innovative platform for accessible cancer diagnostics.

